VBWG - Resource Item

Resources

Quick Order
About Create Profile Login
Email: Password:

Slide Lecture Programs
Postintervention Continuum of Care: Focus on Lipids cash advance cash advance
cash advance cash advance
November 1, 1999
Table of Contents - 86 slides
No.	Title
1	Postintervention continuum of care: Focus on lipids cash advance cash advance
2	Content outline cash advance cash advance
3	Leading causes of death for all males and females cash advance cash advance
4	Percentage breakdown of deaths from cardiovascular disease cash advance cash advance
5	Adjusted rates of in-hospital outcomes after PCI by year of procedure cash advance cash advance
6	Prevention of stent thrombosis: Overview of key trials cash advance cash advance
7	Coronary angioplasty vs CABG: Overall survival and survival free from Q-wave MI cash advance cash advance
8	Coronary angioplasty vs antianginal medical therapy: Greater improvement of angina cash advance cash advance
9	Current use of PCI cash advance cash advance
10	Natural history of atherosclerosis and postintervention: Important differences cash advance cash advance
11	Pathobiologic responses to intervention cash advance cash advance
12	Postintervention: Two different pathobiologies cash advance cash advance
13	Management of atherosclerosis and postintervention: Important differences cash advance cash advance
14	Percentage of patients receiving drug therapy who met NCEP treatment criteria cash advance cash advance
15	L-TAP: Many high-risk adults are not reaching LDL-C goals cash advance cash advance
16	L-TAP: Distance from LDL-C goal in patients with > 2 risk factors cash advance cash advance
17	L-TAP: Distance from LDL-C goal in patients with CHD cash advance cash advance
18	Cardiologists and primary care physicians: Achieving NCEP goals cash advance cash advance
19	Cholesterol management by specialty: Physician perceptions vs practice cash advance cash advance
20	Risk factors and endothelial dysfunction: Mediator role of oxidative stress cash advance cash advance
21	Mechanisms of oxidative stress cash advance cash advance
22	Oxidized LDL-C disturbs the endothelium over long-term cash advance cash advance
23	Some consequences of oxidation of LDL-C cash advance cash advance
24	Factors in endothelial dysfunction?early stage plaque cash advance cash advance
25	Factors in endothelial dysfunction?late stage plaque cash advance cash advance
26	Oxidized LDL-C: A common initiating factor for cardiac events cash advance cash advance
27	Effect of high-fat meal on endothelial activity in normocholesterolemic patients cash advance cash advance
28	Endothelial function in patients with and without dyslipidemia cash advance cash advance
29	Improvement within hours in endothelial function following ischemia with LDL-C apheresis cash advance cash advance
30	Vitamins C & E attenuate reduction in endothelial function caused by high-fat meal cash advance cash advance
31	Atherosclerosis timeline cash advance cash advance
32	Some features of vulnerable plaque cash advance cash advance
33	Patients dying with stable versus unstable coronary syndromes: Atheromas have varying composition cash advance cash advance
34	Role of LDL-C in plaque formation and progression cash advance cash advance
35	Clinical viewpoints on plaques cash advance cash advance
36	Progression of atherosclerosis observed in 307 repeat angiographies post-CABG cash advance cash advance
37	Clinical studies summary: Angiography in infarct-related artery cash advance cash advance
38	PCI vs medical Rx for angina cash advance cash advance
39	Complementary effect of major therapies on 3 vital Rx goals cash advance cash advance
40	Coronary artery disease: Should plaque stabilization be a primary goal? cash advance cash advance
41	LDL-C reduction with statins cash advance cash advance
42	Target LDL-C levels for initiating dietary therapy: Are they realistic? cash advance cash advance
43	Target LDL-C levels for initiating drug therapy: Are they realistic? cash advance cash advance
44	Treatment decisions based on LDL-C levels in adults with diabetes cash advance cash advance
45	Risk factors for CAD: NCEP guidelines for adults cash advance cash advance
46	Dietary therapy for patients at risk for CAD cash advance cash advance
47	Major classes of drugs to reduce lipids cash advance cash advance
48	Achieving NCEP goals for LDL-C cash advance cash advance
49	Achieving NCEP goals for LDL-C cash advance cash advance
50	Benefits of aggressive LDL-C lowering cash advance cash advance
51	Post-CABG: Aggressive vs moderate LDL-C reduction cash advance cash advance
52	Post-CABG: Aggressive vs moderate LDL-C reduction cash advance cash advance
53	Post-CABG: Aggressive vs moderate LDL-C reduction cash advance cash advance
54	Post-CABG: Angiographic vein graft outcomes cash advance cash advance
55	Post-CABG: Event rates by cholesterol group cash advance cash advance
56	Post-CABG: Study summary cash advance cash advance
57	Post-CABG: Aggressive LDL-C reduction benefits patients with other CV risk factors cash advance cash advance
58	CURVES: Study design cash advance cash advance
59	CURVES: Study methodology cash advance cash advance
60	CURVES: Clinical characteristics cash advance cash advance
61	CURVES: Comparative LDL-C reductions across dose ranges cash advance cash advance
62	CURVES: Comparative efficacy of statins cash advance cash advance
63	Patients reaching the NCEP-recommended LDL-C concentrations with statin treatment cash advance cash advance
64	AVERT: Atorvastatin VErsus Revascularization Treatments cash advance cash advance
65	AVERT: Study rationale cash advance cash advance
66	AVERT: Major exclusion criteria cash advance cash advance
67	AVERT: Overview of study procedures cash advance cash advance
68	AVERT: Primary efficacy assessment cash advance cash advance
69	AVERT: Secondary efficacy assessments cash advance cash advance
70	AVERT: Baseline patient characteristics cash advance cash advance
71	AVERT: Ischemic events at 18 months cash advance cash advance
72	AVERT: Ischemic events at 18 months cash advance cash advance
73	AVERT: Time to first ischemic event cash advance cash advance
74	AVERT: Incidence of first ischemic event by time cash advance cash advance
75	AVERT: Summary of lipid parameters cash advance cash advance
76	AVERT: Safety evaluation cash advance cash advance
77	AVERT: Summary cash advance cash advance
78	Revascularization and lipid lowering cash advance cash advance
79	Revascularization and plaque pathology cash advance cash advance
80	Continuum of care cash advance cash advance
81	ACT cash advance cash advance
82	Clinical challenge: Aggressively ↓ LDL-C to ↓ CHD events cash advance cash advance
83	Summary: Postintervention action plan cash advance cash advance
84	Postintervention care timeline cash advance cash advance
85	Postintervention care timeline cash advance cash advance
86	Postintervention care timeline cash advance cash advance


Home \| Literature Update \| Journal Link \| Resources \| Meeting Highlights \| Members \| About VBWG \| Web Links